• Innogen Pharmaceutical, the first company in Asia and third globally to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, on its HK$683 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.*
• Haitong International as the sole sponsor and other underwriters on the HK$493 million global offering and listing of Qunabox Group Limited, a marketing service provider in China focusing on outdoor marketing for fast-moving consumer goods, on the Main Board of the Hong Kong Stock Exchange.*
• YZY Bio, a biotechnology company dedicated to developing bispecific antibody (BsAb)-based therapies to treat cancer-associated complications, cancer and age-related ophthalmologic disease, on its HK$176 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.*
• Asymchem, a leading, technology-driven CDMO providing comprehensive solutions throughout the drug development and manufacturing process, in its HK$7.64 billion global offering and IPO on the Main Board of the Hong Kong Stock Exchange (the largest healthcare Hong Kong IPO in 2021) .*
• Citigroup and Huatai as the joint sponsors and other underwriters on the HK$210 million global offering and listing of Cryofocus Medtech, a medical device company in China focused on minimally invasive interventional cryotherapy, on the Main Board of the Hong Kong Stock Exchange.*
• Citigroup and CICC as the joint sponsors and other underwriters on the US$225 million global offering and listing of Sino-Ocean Service, a comprehensive property management service provider with extensive geographic coverage in the PRC, on the Main Board of the Hong Kong Stock Exchange.*

*Matters may have been handled prior to joining Paul Hastings.